SCHEMBL19729367

SCHEMBL19729367

CC(C)(C)OC(=O)N1CCC(Oc2c(F)cc(C(=O)O)c(F)c2Cl)C1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 8/20 0.43
NPBWR1 P48145 1/20 0.42
MCHR1 Q99705 1/20 0.42
GPR119 Q8TDV5 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TOP2A P11388 1/20 0.42
PIK3CA P42336 4/20 0.41
USP30 Q70CQ3 1/20 0.41
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PIK3CB P42338 2/20 0.40
PIK3CG P48736 2/20 0.40
S1PR3 Q99500 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19729447 0.92 SMN1; SMN2 (0.40) NPBWR1MCHR1GPR119SMN1; SMN2TOP2A
SCHEMBL19729370 0.89 PIK3CD (0.45) PIK3CDNPBWR1MCHR1GPR119PIK3CA
SCHEMBL19729369 0.86 GPR119 (0.41) PIK3CDNPBWR1MCHR1GPR119
SCHEMBL21341518 0.84 GPR119 (0.39) PIK3CDNPBWR1MCHR1GPR119SMN1; SMN2
SCHEMBL28272884 0.81 SMN1; SMN2 (0.47) SMN1; SMN2USP30MEN1USP2HPGD
SCHEMBL19729448 0.77 USP30 (0.38) GPR119SMN1; SMN2USP30MEN1KMT2A
SCHEMBL9728559 0.76 TOP2A (0.49) TOP2AMEN1HPGDKMT2AHSD17B10
SCHEMBL30791458 0.75 S1PR3 (0.43) PIK3CDGPR119SMN1; SMN2PIK3CAUSP30
SCHEMBL5970964 0.74 GPR119 (0.56) NPBWR1MCHR1GPR119
SCHEMBL3160201 0.74 GPR119 (0.49) NPBWR1MCHR1GPR119SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190276407-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2019-09-12 US disclosed
US-20190276407-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2019-09-12 US disclosed
EP-3473616-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF Wakunaga Pharmaceutical Co., Ltd. (JP) 2019-04-24 EP disclosed
EP-3473616-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF Wakunaga Pharmaceutical Co., Ltd. (JP) 2019-04-24 EP disclosed
WO-2017217441-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF 湧永製薬株式会社 2017-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276407-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF CTR9, PYCR1, ACAD9 PIK3CD 1985/4885NPBWR1 92/4885MCHR1 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.